NEOS - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for holding. Good morning and welcome to the Neos Therapeutics' Third Quarter 2018 Financial Results Conference Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow.

remarks, CFO turning of opening to call and Eisenstadt, Richard Neos introductory I the am over For Therapeutics. Please go ahead.

Richard Eisenstadt

Officer. Thank our to I by CEO; our on our conference everyone am in press and joined XXXX corporate site Chief is results morning, Tom we and results available which financial morning, call. you. financial our This at highlights Jerry our and Web Commercial McLaughlin, release, third McDonnell, Good quarter issued welcome www.neostx.com. Today,

we to forward-looking Before like statements. regarding I'd the following begin, read

growth this statements ER of Act During Reform forward-looking related our XR-ODT, Adzenys solely suspension, the business pipeline of product activities, to and call, oral made development our and and the provisions and commercialization Litigation NT the are Securities technology, of considered and capabilities Cotempla XR-ODT activities be XXXX, through the XXXX to the our we will Private business, commercial Harbor timing, Safe including make of that financial our development our statements product our Adzenys product and progress, expansion pursuant the capabilities of research may of concerning including profit and position. business of opportunities candidates, in our

the associated candidates. risks development uncertainties results views differ including and our be to today date. often of should limited but expectations, Forward-looking These subject statements actual only statements not of These product inherent expect, cause indications and reflected with subsequent that as as such of expectations. materially could variety any risks of anticipate, we be with are commercialization a to as may and identified upcoming words we statements future similar and views our representing products to from or of reflect as upon our not

turn filings. in the other XX-Q now SEC and could our and a Jerry. to to contained other our call those please factors risks that of material the I most affect our recent actual For results, important will refer discussion over Form

Jerry McLaughlin

you, morning and Rich, good Thank everyone.

for focused Neos current business, development have quarter in CNS weeks third our evolved The while we subsequent expanded commercial as very time we our also pipeline. and exciting grew been a ADHD

On growth franchise, both market executed for we successful prescriptions our strong share. achieving front, the back-to-school a ADHD quarter-over-quarter for and strategy commercial very

the front, million announced that sialorrhea. closing new addition announced offering in to the a our On the corporate chronic of the of stock for NTXXXX proceeds underwritten pipeline, development of $XX.X growing And of public company. we in October yesterday of the treatment common net resulted CNS Neos regarding entity late chemical we

been consistent accelerate great earnings during discussed our path and assessing last As but that profitable prescriptions news not share. and a evidenced multiple we call, company. by strategy feedback The proven believe the as becoming is value our as only that market to patient franchise levers pull evidenced physician market can quarterly have by continued by are to also our and there Neos' in ADHD has positive growth commercial in

net revenue expect we programs resulted growth franchise. for our our pack more third the adjustments in to continue positive we adjustments per already addition, the made assess coming our to initial the commercial In that impact months some XXXX example as ADHD weeks profitable to in support strategy quarter have in and commercial we on have over

of third the performance. me summary quarter now a commercial to turn Let

X.XX% a XXXX, NPA. XXXX to Market share for XX.X% ADHD most total XX, surpassed for $XX.X the and the and pack approximately second Total prescriptions of our ADHD X.X% October share increase our X.XX% ADHD second XR-ODT in data reporting Third the third our XQ per franchise in franchise Adzenys XXXX time IQVIA to franchise increased for from according ending a for with with represents of Net to XXX,XXX XXXX Market is quarter for X.XX% of revenues by $XX.X prescriptions XXX.X% increase over XXXX million per quarter prescriptions versus week net quarter grew and third were was million quarter quarter in a the third compared X% first to which in growth the quarter recent the for represents of which revenue the $XXX of the third the continuing of weekly increase. compared XXXX. quarter. quarter revenue third XXXX. for to pack $XX quarter quarter XXX,XXX XXXX by net revenues for of a

resulted the this pack be net Going for a and continuing will In summary, the Adzenys franchise in Cotempla. entire on of sales, increases key to performance prescription metrics; market focused the forward net pack. ADHD share, following Neos for will we for be increase revenue and and the both and each relentlessly company team quarter the per management for key volume, the metric per results net for revenue

care. retardation significant with significant in treatment odor, infection, and Neos the disease, condition known Pharmaceuticals NRX a with stigmatisation cerebral micro for to the of from receptor medical and muscular particle developed patients psychosocial antagonist including or will license candidate sialorrhea and our salivation utilize NeuRx the product lead of Parkinson's be This dependency ALS. patients now of excessive perioral now be as managed month last is NTXXXX conditions will patients selective a NTXXXX and physical sialorrhea is entity chronic dehydration, treatment Turning such XXX neurological on chemical as and chapping, a adult address exhibit pipeline drooling. that to foul technology. increased unmet as not complications a will Neos where announced new can and an adequately mental palsy, Sialorrhea to pediatric for level needs

our salivary can the already in acceptable of selectivity of medically for tolerability therapies. for who to Due these new a offer X.X administered disease ability caregivers titration which frequency an develop isolation approved and plans and of dose currently profile daily seeking regimen, drug product formulation condition. technology from as provide are to which and more an is of will treat and NTXXXX urological urological your in over improved will for that, if an complicated options pharmacokinetics an an comfortable burden helping and approved these to offer complex already to that Neos option regimen. create more swallow tolerability profile the once for million We With that of dosing NTXXXX and patients the This molecule millions caregivers the and their and the can additional that more lead the reduce drug easy available believe no patients. to and so provide dosing All micro required. of orally N-desethyloxybutynin dosing treatment worldwide patients optimize NTXXXX is condition of treatment this physicians they to or many safety an the approved delivery particle stigma improved glands twice will receptors with the treat patients U.S. suffer with the lives. active them metabolite oxybutynin route disorder overcome this associated to an new

the a parent data program benefit As for NTXXXX to substantially existing development ability result, for the from leverage is molecule. to the preclinical expected

a pipeline we and take is well-suited it bring would to compound disorders beyond our to as opportunity pipeline, to ADHD. NTXXXX neurological including nervous overall our in our technology market begin building opportunities address addition focus exacerbate current the this to associated broader While disease delivery explore step for is central focused Taking with drug or that system core it a symptoms strategic the to first burden. develop and time

delivery have molecular to PK we in the case advantage profile NTOXXX. in patient We as complete able it entities to XXXX. not At technology, new being improve in formulation and Neos release our by to existing pilot of products also actively drug are the work benefit development of to only leverage and but modified expected of applying clinical proprietary the

that with of compared technology its Our drug release applicability value the maximum believe a pharmacokinetic unlock can a provide potential create technology uniquely We approach release particles current treatments. profiles. molecule of micro broad care and our a the because generate standard to modified to complex to superior has delivery has the the capability properties of

in-house acquisition for and actively assets licensing both to development continue established additional and infrastructure. could that evaluate our commercial We on-market potentially amortize opportunities stage

some As Neos. on updates evidenced the of the the for vision you future by very We're providing today. can see focused as of I'm is

best pharmaceutical company specialty for still and path profitable ADHD to it in this by we're our fine-tuning the specialty customers significant our difference is seek providing become successful CNS broader lives. value tomorrow, We forward be as our summarized today. vision making can While of become marketplace at competitor the patients' to and highly a a in Neos

and three, and to one, current short goal of on realizing company. enhanced In success continue the that decisions the business, Neos franchise important focus driving identified have we will relentless a ADHD becoming commercial optimize for long-term. business two, accelerate profitable We'll forward, that focus success. Going excellence several driving with operational summary, both our that our and of our are profitable to growth to path taking and application efficiencies on and a the the profitable growth analytics in of rigor our important enhance executional actions key making is

development micro particle to profitability, existing of on well while acquisition our Rich, can employ our as marketed strategy forward a as continue building pipeline employ acquisition seek financials. currently robust the look our through pipeline. to and through We will CNS informed to to leverage internal license delivery our products or will and transactions product infrastructure. as continue to that that I We commercial to build review now execute path over - call the technology keeping turn focused our you we our

Richard Eisenstadt

Thank Jerry. you,

debt XXXX paid due principal May of in man, or announced right X.X XXXX with by exceed the XXXX of offering company $XX.X million adopting approximately our our million we exercise and including of To keep in principal we and the $XX meant commissions guests to pay milestones. either finance for certain or in paid Also have for have financing. believe with with in equity cash financing restructure that pursuant stock completion allotment principal This company recent expenses we recap we amendment revenue the future second due alliance our aggregate. and of net a May the the finance to we million the our May to week obligations. the underwriters payable and to May interest option its also $X.X common the underwriting upon million. under transactions service not debt Following achievement sufficient XXXX Simultaneous to proceeds we debt of full shares shares closed our provides [indiscernible] the the be and discount in otherwise an profitability payment of option upon after the this revenue increased facility the

to for not share has X.X $XX. Deerfield exceed conversion the in such Additionally stock right a the into XX% average price of under principal greater the of remaining shares and equitize of weighted the of at average common period the the aggregate stock immediately price trading of to preceding million day facility per conversion three the shares of common value the

September product ended compared the Turning in $XX.X $X.X months for to period XX, three the quarter XXXX same were revenues for total the million million, XXXX. to

product $X totaled of revenues the Cotempla mentioned For ADHD revenues net net including as $XX.X sales were quarter million for negligible. $X.X Adzenys XR-ODT million million. Jerry ER Sales and of Adzenys XR-ODT

for seasonality Recall Jerry each of and XR-ODT Adzenys that pack $XX per Cotempla XR-ODT. per the net deductible were is generally topic pack and for for our of adjustment Adzenys Cotempla XXX. second revenues versus As in third for period improvement product as XR-ODT insurance quarter there adoption quarter the quarter, net some XR-ODT mentioned, pack high comparison but $XX $XX XR-ODT net a of revenue contracts so to XXXX $XXX per Adzenys third was we revenue after revenue the customers' new plans see

in practice reminder not at X, prescriptions As does estimating track the now company wholesalers January to upon product fill return the the versus rate prescriptions. we basis. past Selling the a revenue point adopted a time to of we recognize recognizing a on product XXX, wholesalers quarter-over-quarter deliver while necessarily effective XXXX, the revenue

expenses our operating lower XXXX. The R&D to three replacement million XX, expense implemented a with wholesaler track prescriptions. ended $XXX,XXX We three of a XX, three quarter in in September unit includes stock inventory our XXXX development months period of period compensation inventory profit had XXXX to programs. the at compared generic Gross the for XX, XXXX. was months out reflect compared the months associated to that process. $X.X for scraped approximately for XX, in the the $X were million time we've and production cost. to September cost in for XXXX. associated over post-marketing the for $X.X as fact does $X.X XXXX months three in write-down ended to our R&D for inventory September ended of not administrative million efficiencies is that XXXX and gross $XXX,XXX million the a principally General expenses same sell we higher profit FDA the ended into XX, Tussionex million down compared we In expenses, product revenues for with of saw September same inventory, September same were XX, million clinical commitments continue were cost cost $X.X $X.X also the as a our months compared period ended well for three of ended XXXX Net million pipeline with cost XXXX. $X.X September for

and of three same months XXXX. period million to million million XX, Q&A $XX.X the for loss to $X.XX $XX.X expenses we'd to a the for compared September the a September the now to Operator? marketing loss XXXX selling of same With portion Net or per per call. share in was XXXX, three were months of the ended or XXXX. like for share, in For the that, $XX.X XX, $XX.X period million loss $X.XX turn ended compared

Operator

may will Fitzgerald. comes And from first Instructions] you from We question take Louise [Operator any have. now questions Chen Cantor our

is line Your open. now

Louise Chen

taking for few I Thanks here. questions. Hi. a had my

on I was NTXXXX So your the first had product. question on in-licensing. Congratulations

this with this more who in might just more space additions And if XXXX then is with is XXXX margin. you. elaborate upon into and to we opportunity then secondly are XXXX you areas could additional and a the you see could had of end market build something opportunity before more should How there if compete the to for of to or curious would you competitors? if year housekeeping the last add with I like think respect any Thank gross you your curious existing Just pipeline you? to and or OpEx we on franchises? And And would question those? respect XQ your about in what also the

Jerry McLaughlin

for them what day is I more anticholinergic. questions. all require significant have U.S. the about older significant that patients right, But issues cover several treatment and I'll remind overarching three the All Okay. thanks the in Louise sialorrhea a The us week try about over require market don't titration are please million they're the agents weeks worldwide. options if and non-selective excites anticholinergic titration million tolerability so chronic the rigorous dosing NTXXXX a me. a non-selective and times regimens or with associated X.X being

we indication. On that the toxins are used the the are other have of that there sort of high this end, botulinum for some at spectrum end being are

receptor here versus being with we that the these with a antagonist we was anticholinergic So patients when We huge it's there dose older seemed [indiscernible] a insert, products Mouth Dry superior outcome muscarinic with patients can work to profile we we easier palsy a to a many and selective has deal the our will the provide have particularly issues. our for regimen cerebral their tolerability one non-selective example that upon gap did for a constipation XX% is right middle be agents to that that vomiting product and product a the of XX%. about better tolerated improve better caregiver like XX%, for what think and caregivers, those for believe from

exquisite profiles peaks step substantial it's particularly micro-particle we a where pharmacokinetic receptor to is product the very think CNS the the first micro-particle We disease ground muscarinic tolerability leveraging only We We but sensitive we company issues with in part brain So hyper the patients that so avoid drive can in the delivery the profiles. our pharmacokinetic great we where with to pharmacokinetics really are physicians that so put troughs molecule we a very not a with take this develop we of flag only believe impacted and can the improve portion a technology. greatly to can feedback state very we our in as clearly improved ADHD, signal with from a the combination ADHD, also and delivery we're sensitized smooth applies see antagonist, brain, that's of about having not across delivery a of profile can it a I've already was thought it variety technology. that able get matter have we technology and CNS disorder. that think have of a but and selective itself to

forward, technology underlying refer going CNS MS like and our if to area area you we in symptom. We not that broadly think the an about may the pipeline but care treat the like leverage supportive as internally we So neurology. to more particularly we

to Therapeutics and I That's MSK. can Acorda we're here what with CNS indications. did think a variety it doing what of across a [indiscernible] company with [indiscernible]

look area. for that in we more So

far timing, but we'll I the in As forward see as go here, be searching all immediately don't we we time, something actively this and be wouldn't pipeline. We to we'll opportunistic. have we're the - as expect searching actively with quarter, say throughout

we we're the to maintain ADHD a see XXXX something strategy, something right going months as we our infrastructure particularly our additional entertain our addition, it's commercial add to leverage to focus at. products In we're on could will that's to were driving forth three looking actively always on in going six look opportunity. in the franchise, we if next And real evolving while we're commercial to that's

Richard Eisenstadt

been. Louise, on continue operating it the run quarter, expense think expenses, for the fourth has I as should operating rate

less We expense indicator selling for that something good $XX a million. and we guided felt than for would where had of kind would is SG&A previously marketing QX be. think that be I QX

the expense. $XX million G&A year. is tracking on to R&D is year. the not $X million clear, probably that roughly that And million year. to of to think is this of mid-XXs be somewhere expense million I cash going it's all to on just $XX $X around is and non-cash be

we now, in a roughly - I next next our the haven't of right year. we're operating in reduction expect think for so haven't expenses We'll date, We can but later that in year. into budgeting as the process do going to you guidance issued expenses

Louise Chen

you. Thank Okay.

Jerry McLaughlin

Louise? sorry, I'm

Operator

[Operator Instructions] Ms. Louise?

Jerry McLaughlin

I Operator. think to the go we question, next can

Operator

from Wells from our Maris And next ahead. go comes question Fargo. Please David

David Maris

I morning. of a a Good questions. couple late, jumped bit but on little

on see next you net, are the So cash think year's to out. at at to then as is Thanks. rolling how point? you balance, capital do takes that you that where structure or contracting the looking that? gross when address you you our the And separately, How maybe current think of you this first and considering are just

Jerry McLaughlin

David, handle the and first I'll Rich then take can second the question. question

pack As pack. at and reported $XXX revenue net to how for it metric of for focused net per on - that's our per that's David each sort of an we we brands now, gross for internal revenue look and

forward, pack, on of on our our off focused we whack. we optimizing relentlessly our more the realizing go revenue value forward, things patient we improving And net are are we really As focused per affordability. see relentlessly going

programs we liability make products contracts. continue to they enhance And we and at Neos availability look and We our at to and finally, our discerning and both how an we're enhance commercial a are our the distribution to and managed between affordable and sure to go co-pay. to as provide looking strategy taking our really in very pharmacy forward. But those hard reduce also we - looking contracts at for patients Medicaid care We're our our patient. committed will work distribute going forward look

guidance, But the XXXX, XXX of us a in is see of XXXX. increase upside material going at deductible We contract seasonality we specific - we'd definitely. commercial our look our for if revenue have will a caution that albeit see but focus very occurs the all in we continue throughout Medicaid be that engage to not and take hard Period. course from disappointed with the the With high forward. said, we'll giving we We're contracts that net don't long during opportunistically in per pack a

Richard Eisenstadt

the profitability financing we believe that have company. recent debt increasing so our to to restructuring So we meet we debt our on believe sufficient our combined have get cash and we gives with financing the overhang and solved revenue to had that us previously obligations

debt don't continue we our right We structures options at for Again, a looking lower been while cash that quite for now. a cost there's to need will but always to debt looking by sheet. balance additional look different perhaps at we've have at

to profitability lines can capital you and accounts think are other course burden of along receivables options we about previously there's move your company. that lower towards working that As something your those us it's available we've which lines, get always I talked debt on to

David Maris

very much. Thank you Okay.

Operator

Ken Thank our Company. next and ahead. comes you. And question Please go from Cacciatore Cowen from

Ken Cacciatore

guys. Good morning. Thanks,

and doing Just to obviously, differently we're be wanted bit on what more little improving. a care down drill managed seems to it

up So, we can where giving to some actually position at a make are covered lives covered lives profitable. you lives more now or are covered we're now this about growing we talk

deeper little or we bit So a wanted size. Are going you're folks also what's down force more in the are a some here understand perspective, launches, of on been that we on the just that's force that from much a how there of you're context as losing just And sales detail can to were now doing around bit you a differently little detail differently. bit Thank then into sales things adding as you. doing of terms progressing. in drill little

Jerry McLaughlin

as are alluded much handle does are whether at at Sure. costly They're to taking commercial adequate a engaging it's look a you hard know very hard long thanks clearly company we're we it's net getting the the question, leader. have for taking we'll the they already I lives increase very going a Can to then in we or to forward. return provide covered lives return are a in contract as say pretty net lost ensure But Medicaid very versus first, the and I uncovered to managed it look and sense, hard think I make you the think coverage without contracts. and and contracting care

diligent if we're forward. about best for business our they're - determining best being real the for decision So going

covered So whether an say to in increase think we'll lives XXXX the I versus it's have decrease. hard in

will drive favor We as scales our profitable good opposed will to in the the said tip where commercially growth to focus lives leader we that covered provide our prescriptions. loss for That always affordability patients in marketplace. resources we

pinpoint hard I it's but then from to we'll potential sum it we had side. number, in be if if we'll - additional the So up, to and play a be Medicaid very space on strategic the contracting selective in commercial

As far force as the sales size.

business these internalized bring We decisions your maintain we time. sales the for changes as on constantly where at interest still have of our you're to programs been of XXX lastly sense, how territories give have the we sales of no costly second That at force, year a target the terms made sales roughly are And we as forward. made and is aware quarter that us of in force to no one said, are to aware active and folks best programs this force development the always going you and the in this market. looking to how just can

shareholders which you very want Just just that your trying Thank level you. to understand excited are the profitability get want you the see versus enthusiasm, to to understand that of - balance?

Richard Eisenstadt

Yes.

of the NCE molecule. greatly accelerates we active cost timing that but question the preclinical an excited confident very an asked you glad NTXXXX I'm and can which we're things Therefore but it's the is about of it's gets reduces the the safety metabolite really that an the of us fact existing existing one leverage Ken, only database program. not So

development, expect to XXXX. XXXX we and could in through have We will in fallen and development in we're work be PK by NDA now move early some now we

rigid - for program, given you cost the spend or and specific on very of decisions can guidance the assure the spend the no-go haven't we'll have the And but two. modest program. I early modest it's is very the cost in go, year We

from back So NeuRx about then perspective through And milestone totals approval. that million towards is the very the liability low. a is program development from to And of approval. payment a it most $X ended

we're a the hear very you this the of and a of So not but about from - conscious like of market we also spend really attractiveness things gated and that's we the spend program one perspective. only amount from from

Ken Cacciatore

Great. Thank you.

Operator

ahead. comes Thank from go Securities. Jason Please next JMP from you. question Butler And our

Jason Butler

Hi. Thanks question. important the been of an has commercial care strategy. Obviously, managed the taking the assessment part piece your for of

Europe managed You considering? what to the and outside adjustments. looking potentially of about just that the mentioned levers additional and make you're pulls that talk is care evaluating you're Can you

Jerry McLaughlin

a value we at frequency the Jason Yes, ADHD among prescriptions just constantly accordingly. not our weighting we'll of their service increasing a looking things be and we I a profitability way but within did as It's a their primary more with objective return thanks pays my I our deploy from comments, front - think right. and question. from representative upon our try audience a at determine our to target we'll in and managed to - piloting investment, test geography, my we'll elevating it also business for see out our everything based we in we're our group that's environment volume There's will of if deploy, the our on that mean, we're that our of back example works looking are lots fast that, driver learners. customers. allocating looking for We'll or not. we're and very customers We're effective resources cost pilot a within differently prepared care resources really at if moving comments, and and to looking on of rigor at, of to analytics

through expect going future. the very now to those assessments we're those near and deploy So in right we'll

at that feel for are the addition, may forward. there ship are relationships fulfillment we affect pharmacy, cannot beyond reduce physician big the our traditional those only our opportunities pharmacy going abandonment create ecosystem be networks. retail patient We out and but really looking sales types our in up things to products our So, of representative of and distribution and cost better that set some to enhance to a box,

So of of we're gives well. things as there a are where beyond a number you taste headed. But of that that sort

Jason Butler

Okay, great. Thanks for taking the question.

Operator

you. And from from Thank next BMO [Operator Instructions] Nachman comes Gary Capital. question our

now line open. is Your

Gary Nachman

Hi. Good morning.

the net, target said increase, achievable Gerry, how to if discontinue [indiscernible] Adzenys-ER that traction was a it, of product sense still in inventory will to that back end, but point? And XXX at if could make it maybe Just gave does is much XXX you not last any year quarter I you know, you quarter And by drawdown that to Rich, with quantify that? the third some the you're gross getting to

Richard Eisenstadt

Yes.

take I'll Gary, first. financial So, questions the

we nearing yes, had plans because into think actually XXX the will accelerate high guided deductible what with point previously QX at be for the I where you XXX Adzenys-ER. for in. higher exceeded RevRec, come that. new you - XXX interesting, sell a we've So, gets in adjudicated already the QX And plans deductible to the

could Gerry So of the a offset little currently or talking in strategies some around that QX about, so a I by be is QX of is. bit it's headwind think where

then similar over for XX believe year, of look be or over instance, similar from not XXX, if up be more right marginally same, the to sure think it even course dramatic think you can see are where different, step so. of it's but next or don't not And we up in going course these compared XX last have I'm down or year months over to numbers the now. I the back So, to I up will step to I

Gary, it's think have QX. Regarding probably I but of I envelope calculations, specific in and a the inventory don't that drawdown, I million that around back $X the on numbers do

Jerry McLaughlin

we're a of And right. Gary to that your always is - we Adzenys-ER, will at, question question looking

I and think We'll the makes coming volume, Adzenys-ER very ourselves in question it's skew. continue for time short it - quarters that is be that to opportunity sense to months we'll that and been position forward with there on an if market. asking a meaningful to assess constantly the move determine but if

Gary Nachman

pleased were step that accelerated with And I couple school little back thought a the performance Okay. others, take a would I bit that the but you said in have just you then back-to- season, if you maybe you of a more. mean Jerry,

So was terms in just standpoint there. adoption that patient little bit more of actually adoption, a physician a back from anything color holding there commercial

Jerry McLaughlin

because share. were grow I market we think in volume we pleased and Yes in very

we than So the share our was it's maybe to we performed pleased comment the he's business, Tom? off Tom the in for very market, close third lion's how of higher trough market to growth the our took quarter. we're relative because to very but and market good

Tom McDonnell

Good morning Jerry. sure, Yes, Gary.

back-to-school is right some of rider products HCPs talked prescribers most we think a school grow to for XX we there. exceeded sell up per both extremely in importantly So of and really base, the as our pleased back results, we go focused share. highlighting quarter we to the needs focused the and in and on we of our as XX,XXX our time, prescribers. last yes, high prescriber scripts on about the But TRx's was of performance we we sort the Most and call, I first they with market portfolio were TRx with that and a current runway quarter importantly patients per grew lots

growing products important quarter-over-quarter the was an during In able by point back-to-school market overall we and is X%. But fact yet to were grow down incredibly again. market by share XX% both

should see out throughout most is the we're and back-to-school and we to that year, first important the fourth very So play quarter into quarter critical. going the continue then pleased with

important we I year. period, next the to that of time play work into and see out this So you'll the the in that did share rest throughout think grow year

Gary Nachman

we But that in in what have and saw if bigger earmarked think recent going And you can that could failure, lastly have cash do but of you say or could I more we be feel and towards a us of opportunities that a of sense products It's bit terms how come be bring in looking a more might to could parts in use do be you try and hard much with give your that raise know then to of you moving aggressive that for. you're you with product little lot it you get is business the Okay. the aggressive more sooner. recent development. like terms Thanks. just the

Jerry McLaughlin

really obviously Gary, know you I think that could change, it right.

in might investment I a I of think at sources a to a really see opportunity aggressive point. we a if a more fit. something be deal of right, asset. it be. could bigger and we I home will hate that could find right funding particular The think the it be say pinpoint opportunity we think warrants number We're I strategic also think we - Gary on if if way on that's it on - this our we find where market we will it's entertain. other find if if strong really attractive would NTXXXX I ballpark But to But the think

Tom McDonnell

an of quiver But structure of cash you lot it carries have really on lot so more helps is a that. a deal opportunity of now levers. giving opportunity about us our having evaluation. Obviously in some And it hours

Gary Nachman

Right.

Okay. you. Thank

Operator

in this thank today's And concludes you. time. today's at conference. the for program. This Thank showing I'm participation questions no you gentlemen, further queue Ladies in and

all have You may disconnect. great day. Everyone, a

Neos Therapeutics (NEOS) 9 Nov 182018 Q3 Earnings call transcript